Back

Primary prevention of heart failure with glucagon-like peptide-1 receptor agonist

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Prevention of heart failure Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Keerthenan Raveendra

Leeds (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Discussant - Prevention of heart failure
Presentation thumbnail
SCORE2-HF risk prediction algorithms: new models to estimate 10-year risk of incident heart failure in Europe
Doctor W. Shi (Cambridge, GB)
Abstract Slides Video
Presentation thumbnail
The added value of ECG on the PREVENT CVD risk score for the prediction of subclinical cardiac disease - insights from Project Baseline Health Study
Mrs D. Gjermeni (Stanford, US)
Abstract
Presentation thumbnail
Fewer heart failure hospitalizations and improved survival with CIED algorithm-based remote monitoring on top standard of care
Doctor U. Aslan (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Association of systolic blood pressure time in target range with heart failure risk and mediating roles of NT-proBNP, hs-cTnI, and eGFR: novel findings from the SPRINT trial
Professor R. Huang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Prevention of heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved ejection fraction - A meta-analysis of randomised-controlled trials
thumbnail
Congress Presentation
Cardiometabolic benefits of dual GLP1-RA and SGLT2i therapy in patients with HFpEF, T2DM, obesity, and obstructive sleep apnea: a prospective study
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources